Multiple outpatient visits are key to success opioid-use disorder treatment

People with opioid-use disorder who enter treatment are at risk for relapse, overdose or death if they engage in less than two outpatient visits in their first month of care, according to a study coauthored by Rutgers researchers.

The study, published in The American Journal of Psychiatry, examined the likelihood of patients continuing treatment for opioid-use disorder during their first month in care based on how often they engaged in outpatient visits or other professional services.

Engagement in outpatient visits or professional services appears to be a necessary condition for adequate care retention. Monitoring this engagement may help identify and address barriers and disparities in outcomes."

Stephen Crystal, Study Coauthor, Director of the Center for Health Services Research at the Rutgers Institute for Health, Health Care Policy and Aging Research and Distinguished Research Professor at the Rutgers School of Social Work

Starting an individual on medication for opioid-use disorder and then retaining them in professional care are two evidence-based interventions for reducing overdoses, according to the National Academies of Sciences, Engineering and Medicine. Researchers said patients participating in outpatient visits during treatment can be a measure of success for care retention, but there is a need to assess how this measure applies specifically to individuals with opioid-use disorder who are receiving medication, such as buprenorphine, as part of treatment.

Using data reported between 2011 and 2019 from a multisite buprenorphine clinic throughout eight states, researchers examined the relationship between participating in outpatient visits and care retention in nearly 20,000 individuals. The patients were predominately male and non-Hispanic, which is broadly representative of people nationwide who are using buprenorphine for opioid use disorder treatment, according to prior research from study authors.

Researchers found that nearly half of patients who participated in multiple outpatient visits in their first month of care remained in treatment for a minimum of six months, whereas 2.9 percent of patients who didn't participate in multiple visits remained in treatment after six months.

"This finding is critically meaningful and could guide intervention development to prioritize stabilization of high-risk patients early in treatment," said Arthur Robin Williams, lead author of the study and an assistant professor at Columbia University Department of Psychiatry. "Without early engagement, the great majority of patients will be lost to relapse and possible death."

The study's findings align with the priorities of organizations such as the Substance Abuse and Mental Health Services Administration, which support care coordination and peer navigation services early in treatment to help stabilize patients who otherwise might be lost to follow up.

"Many of these services are not currently reimbursable by payers, so insurance plans need to create bundled rates to be more innovative," Williams said.

More research is needed to identify patients at the greatest risk for overdose, said the researchers, adding that further research can demonstrate the importance of milestones in opioid-use treatment to develop care-performance measures.

Journal reference:

Williams, A.R., et al. (2022) Performance Measurement for Opioid Use Disorder Medication Treatment and Care Retention. American Journal of Psychiatry.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
What is the ‘immune self,’ and how can this concept benefit immunological research?